Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives.
Forbion currently manages over €700m across six closed-end funds, including its $200m+ FCFIII fund, launched in 2016, for which Forbion is actively looking for new exciting opportunities. Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s portfolio companies are developing novel drugs, medical devices and diagnostics for high and unmet medical needs. Besides financial support, Forbion helps companies to bridge research and development through the team’s expertise in drug development and company building. The current portfolio comprises around 27 active investments in companies working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system pain management, and the microbiome. Recent examples of successful exits include Dezima sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures).
Forbion also operates a joint venture with BioGeneration Ventures, who manages three separate seed and early stage funds focused on Benelux.
Part of the capital invested from Forbion Capital Partner’s funds is provided by the ERP-EIF facility and the LfA-EIF facility, which is managed by the European Investment Fund, and from the KFW through the ERP - Venture Capital Fondsfinanzierung facility.